Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 28, 2009

Rubicon to Launch Analytical Kits that Use ZyGEM’s DNA Extraction Products

  • Rubicon Genomics’ preanalytical platform products will incorporate ZyGEM’s advanced enzymatic nucleic acid extraction technology. The companies’ agreement will initially focus on diagnostic single-cell whole-genome amplification kits but in the future may be expanded to include products for broader research and diagnostic applications.

    Rubicon will soon launch its PicoPlex™ kits that integrate ZyGEM’s DNA extraction technology, which uses a thermophilic enzyme to extract DNA from samples using a single closed-tube system. The product targets the preimplantation genetic diagnostic and cancer diagnostic markets, which require rapid, reproducible amplification to profile patient genotypes, karyotypes, and mutations. PicoPlex will enable reference labs to begin qPCR, microarray, or sequencing analysis less than three hours after collecting patient cells, according to Rubicon.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »